VERU-111 as an Oral Tubulin Inhibitor Suppressing Triple-Negative Breast Cancer and Evaluation of Novel Tubulin Inhibitors for Cancer Therapy

Author

Shanshan Deng, University of Tennessee Health Science Center

Date of Award

11-2020

Document Type

Dissertation

Degree Name

Doctor of Philosophy (PhD)

Program

Pharmaceutical Sciences

Track

Bioanalysis

Research Advisor

Wei Li, PhD

Committee

Duane D. Miller, PhD Tiffany N. Seagroves, PhD Murali M. Yallapu, PhD Junming Yue, PhD

Keywords

metastasis, microtubules, proliferation, TNBC, tubulin inhibitor

Abstract

Triple negative breast cancer (TNBC) has aggressive clinical features strongly associated with poorer overall prognosis and higher mortality rates relative to other molecular subtypes. FDA-approved drugs, such as paclitaxel, are effective in treating TNBC. Yet, treatment failure is commonly observed due to the development of acquired chemoresistance, which remains a clinical challenge for TNBC therapy.

Declaration of Authorship

Declaration of Authorship is included in the supplemental files.

ORCID

https://orcid.org/0000-0003-4646-5885

DOI

10.21007/etd.cghs.2020.0524

Recommended Citation

Deng, Shanshan (https://orcid.org/0000-0003-4646-5885), "VERU-111 as an Oral Tubulin Inhibitor Suppressing Triple-Negative Breast Cancer and Evaluation of Novel Tubulin Inhibitors for Cancer Therapy" (2020). Theses and Dissertations (ETD). Paper 533. http://dx.doi.org/10.21007/etd.cghs.2020.0524.
https://dc.uthsc.edu/dissertations/533